Experimental drug PTX-100 tested in advanced cancer patients
NCT ID NCT03900442
First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 19 times
Summary
This early-phase study tested a new drug called PTX-100 in 25 people with advanced cancers (like multiple myeloma, lymphoma, or pancreatic cancer) that had stopped responding to standard treatments. The goal was to find the safest dose and see how the drug works in the body. While the drug may help control the disease, it is not expected to be a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Epworth Healthcare
Melbourne, Victoria, 3002, Australia
Conditions
Explore the condition pages connected to this study.